Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — CTAD 2018

28 slides from Anavex Life Sciences's conference presentation, October 2018

  1. Slide 1: Longitudinal 148-Week Update of ANAVEX2-73 Phase 2a Alzheimer's Disease Extension Study

    Slide 1: Longitudinal 148-Week Update of ANAVEX2-73 Phase 2a Alzheimer's Disease Extension Study

    Longitudinal 148-Week Update of ANAVEX®2-73 Phase 2a Alzheimer’s Disease Extension Study CTAD October 2018 Harald Hampel, MD, PhD1, Mohammad Afshar, MD, PhD2, Frédéric ParmenBer, PhD2, Coralie Williams, MSc2, Adrien Etcheto, MSc2, Federico Goodsaid, PhD3, Christopher U Missling, PhD4 1Department of

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentaBon contains forward-looking statements made within the meaning of the Private SecuriBes LiBgaBon Reform Act of 1995 by Anavex® Life Sciences Corp. and its representaBves. These statements can be idenBfied by introductory words such as “expects,” “plans,” “intends,” “believes

  3. Slide 3: Disclosures

    Slide 3: Disclosures

    Disclosures § The studies were funded by Anavex Life Sciences § HH serves as Senior Associate Editor for the Journal Alzheimer’s & DemenBa; he is the speaker of the Alzheimer Precision Medicine IniBaBve (APMI), he received lecture fees from Biogen and Roche, research grants from Pfizer, Avid, and MSD

  4. Slide 4: Agenda

    Slide 4: Agenda

    Agenda § IntroducBon § Background § ANAVEX®2-73-003 Extension Study Update § Precision Medicine Paradigm from Oncology to Alzheimer’s Disease § KEM® plaporm to Select Relevant Biomarkers § Mixed-Effect Models for Repeated Measures with a Linear Time Component 4

  5. Slide 5: Introduction

    Slide 5: Introduction

    IntroducBon § ANAVEX®2-73 is a novel compound relevant to AD and neurodegeneraBve, neurological diseases § TargeBng the Sigma-1 receptor (SIGMAR1) § SelecBve under pathological condiBons while sparing normal physiological acBvity, thus limiBng adverse side effects# § ANAVEX®2-73 is an orally availabl

  6. Slide 6: Background

    Slide 6: Background

    Background § ANAVEX®2-73 is a new targeted therapy in Alzheimer and other neurological diseases § 57-week Phase 2a study: ANAVEX®2-73 was tested in a 57-week Phase 2a study (AV2-73-0021) with 32 mild-to-moderate Alzheimer’s disease demenBa paBents. This study showed: − ConcentraBon-dependent respons

  7. Slide 7: ANAVEX2-73 activates Sigma-1 Receptor Restoring Cellular Homeostasis

    Slide 7: ANAVEX2-73 activates Sigma-1 Receptor Restoring Cellular Homeostasis

    ANAVEX®2-73 acBvates Sigma-1 Receptor Restoring Cellular Homeostasis ANAVEX2-73 Restoring Homeostasis sBmulaBng cells to regain and NeuroplasBcity funcBonality & plasBcity Chaperoning Sig-1R / σ1 = Sigma-1 Receptor Misfolded proteins BIP = Binding Immunoglobulin Protein Source: SchemaBc approximaBon

  8. Slide 8: Overview ANAVEX2-73 Phase 2a Clinical Study

    Slide 8: Overview ANAVEX2-73 Phase 2a Clinical Study

    Overview ANAVEX®2-73 Phase 2a Clinical Study PaBent characterisBcs: - Mild-moderate AD paBents - Age range: 55 to 85 - Clinically diagnosed with MRI and/or PET scans 32* 27* 21* 002 study1 003 study2 (extension) Part A Part B Extension PK: Iv and Oral Oral only Oral only Cross-over administraBon Par

  9. Slide 9: ANAVEX2-73 Phase 2a Alzheimer Extension Study Safety Update

    Slide 9: ANAVEX2-73 Phase 2a Alzheimer Extension Study Safety Update

    ANAVEX®2-73 Phase 2a Alzheimer Extension Study Safety Update § Safety update through 148 weeks: § ConBnued favorable safety and tolerability § No ANAVEX®2-73 related AE or SAE 9

  10. Slide 10: Translation of Precision Medicine Paradigm from Oncology to Alzheimer's Disease

    Slide 10: Translation of Precision Medicine Paradigm from Oncology to Alzheimer's Disease

    TranslaBon of Precision Medicine Paradigm from Oncology to Alzheimer’s Disease § Cancer § Broad spectrum of diseases, characterized by molecular markers specific to different tumors § Molecular test required for treatment decision § ~40% of new drugs have a companion diagnosBc § Alzheimer’s Disease §

  11. Slide 11: ANAVEX2-73 Data Integration and Data Analysis with KEM

    Slide 11: ANAVEX2-73 Data Integration and Data Analysis with KEM

    ANAVEX®2-73 Data IntegraBon and Data Analysis with KEM® MMSE Data Integration ADCS-ADL Scores Delta MMSE Baseline Delta ADCS-ADL Population PK Helps idenBfy paBent Helps idenBfy paBent Scores Evolution selecBon biomarkers selecBon clinical criteria Clinical RNA DNA assessment, WES WES Vital signs, c

  12. Slide 12: Validating Drivers of Clinical Response at Week 57

    Slide 12: Validating Drivers of Clinical Response at Week 57

    ValidaBng Week 57 Drivers of Clinical Response at Week 148 002 study1 003 study2 Four key drivers of response idenKfied at Week 57 with KEM® Improve Worsening p=0.035 ADCS-ADL Delta p=0.030 p=0.023 p=0.012 Week 57 Low Medium High SIGMAR1 SIGMAR1 COMT COMT BS MMSE BS MMSE (n=9) (n=7) (n=8) variant wt

  13. Slide 13: Validating Drivers of Clinical Response at Week 148

    Slide 13: Validating Drivers of Clinical Response at Week 148

    ValidaBng Week 57 Drivers of Clinical Response at Week 148 002 study1 003 study2 Four key drivers of response idenKfied Response hypothesis tested at Week 148 using KEM® MMRM-LME at Week 57 with KEM® analysis Improve Worsening p=0.035 ADCS-ADL Delta p=0.030 p=0.023 p=0.012 Week 57 Low Medium High SIG

  14. Slide 14: Mixed Effect Models for Repeated Measures with Linear Time Effect (MMRM-LME)

    Slide 14: Mixed Effect Models for Repeated Measures with Linear Time Effect (MMRM-LME)

    Mixed Effect Models for Repeated Measures with Linear Time Effect (MMRM-LME) combined with Parameters extracted with KEM® Mixed Effect Model for Repeated Measures¹ - Linear Mixed Effect2 : § Inter-paBent variability is modelled over Bme § Time is modelled as a conBnuous variable, hence reducing the numb

  15. Slide 15: APOE ε4 Allele Distribution in ANAVEX2-73 Study

    Slide 15: APOE ε4 Allele Distribution in ANAVEX2-73 Study

    APOE ε4 Allele DistribuBon in ANAVEX®2-73 Study 6 out of 8 paBents High ANAVEX®2-73 75% APOE ε4 carriers in concentraBon Cohort High AV2-73 concentraBon cohort 4 out of 13 paBents Low ANAVEX®2-73 30.7% APOE ε4 carriers in concentraBon Cohort Low AV2-73 concentraBon cohort à APOE ε4 carriers are 2.4

  16. Slide 16: High Concentration cohort shows 88% difference to low concentration cohort

    Slide 16: High Concentration cohort shows 88% difference to low concentration cohort

    PaBents treated with higher ANAVEX®2-73 ConcentraBon maintain ADCS-ADL1 Performance over the 148 Week Period, vs lower ConcentraBon cohort (p-value < 0.0001) High ConcentraKon cohort shows 88 % difference to low concentraKon cohort In addiBon to ConcentraBon, the significant covariates idenBfied in MMR

  17. Slide 17: High Concentration cohort shows 64% less decline than low concentration cohort

    Slide 17: High Concentration cohort shows 64% less decline than low concentration cohort

    PaBents treated with higher ANAVEX®2-73 ConcentraBon show higher cogniBve MMSE1 Performance over 148 Weeks, compared to the lower ConcentraBon (p-value < 0.0008) High ConcentraKon cohort shows 64 % less decline than low concentraKon cohort Other significant covariates idenBfied in MMRM-LME model are:

  18. Slide 18: Supporting Precision Medicine Approach and Genomic Biomarker Hypothesis

    Slide 18: Supporting Precision Medicine Approach and Genomic Biomarker Hypothesis

    SupporBng Precision Medicine Approach and Genomic Biomarker Hypothesis SIGMAR1 / SIGMAR1-Q2P Genomic biomarker SIGMAR1 Biomarker idenBfied Crystal SIGMAR1 valid at SIGMAR1 is Biomarker using Structure RNA mulBple confirmed hypothesis unbiased provides expression Bme points target of maintained systema

  19. Slide 19: Remarks regarding the ANAVEX2-73-002/003 Studies

    Slide 19: Remarks regarding the ANAVEX2-73-002/003 Studies

    Remarks regarding the ANAVEX®2-73-002/003 Studies § Data rich study (scores, PK, DNA, RNA) provides a unique opportunity to characterize response § CombinaBon of data rich study and KEM® unbiased systemaBc analysis enables idenBficaBon of biomarker hypothesis in a small paBent populaBon § Longitudina

  20. Slide 20: Conclusions & Perspective

    Slide 20: Conclusions & Perspective

    Conclusions & PerspecBve § The longitudinal 148-week data show that paBent cohort with the higher concentraBon of ANAVEX®2-73 maintains the ADCS-ADL score and becer perform at MMSE, along the trial duraBon, when compared to the lower concentraBon cohort § A significant impact of SIGMAR1 and COMT biom

  21. Slide 21: Acknowledgments

    Slide 21: Acknowledgments

    Acknowledgments Thanks to: § Principal InvesBgators & clinical sites’ study staff § Data safety review commicee § Anavex SAB § Most of all, grateful acknowledgement of the contribuBon of the parBcipaBng AD paBents and their caregivers ANAVEX is a trademark of Anavex Life Sciences Corp. 21

  22. Slide 22: Contact Us

    Slide 22: Contact Us

    Contact Us Corporate Office: Shareholder & Media RelaBons: Anavex®Life Sciences Corp. Core IR 51 West 52nd Street, 7th floor Scoc Gordon New York, NY 10019 scocg@coreir.com 1-844-689-3939 www.anavex.com NASDAQ: AVXL ANAVEX is a trademark of Anavex Life Sciences Corp. 22

  23. Slide 23: Backup Slides

    Slide 23: Backup Slides

    Backup Slides 23

  24. Slide 24: Plasma Concentration of ANAVEX2-73 is Correlated with the Administered Dose

    Slide 24: Plasma Concentration of ANAVEX2-73 is Correlated with the Administered Dose

    Plasma ConcentraBon of ANAVEX®2-73 is Correlated with the Administered Dose Phase 2a Study Part A Total average drug exposure over Bme AUC(0 to infinity) Area Under the Curve, 0-24h ANAVEX2-73 Treatment 24

  25. Slide 25: KEM Analysis: Higher Concentration and Exclusion of SIGMAR1-Q2P Variant Linked to Improved Response

    Slide 25: KEM Analysis: Higher Concentration and Exclusion of SIGMAR1-Q2P Variant Linked to Improved Response

    KEM® Analysis: Higher ANAVEX®2-73 ConcentraBon and Exclusion of SIGMAR1-Q2P Variant linked to Improved Response at Week 57 p=0.030 Improve p=0.023 ADCS-ADL Delta from Baseline (Week57) Worsening Low Medium High SIGMAR1 Pro2 variant SIGMAR1 (n=9) (n=7) (n=8) SIGMAR1 Q2P variant SIGMAR1Gln2 Gln2 (n=5)

  26. Slide 26: Gene Markers and Baseline Characteristics improve Effect Size (Cohen's d)

    Slide 26: Gene Markers and Baseline Characteristics improve Effect Size (Cohen's d)

    Gene Markers and Baseline CharacterisBcs improve Effect Size (Cohen’s d) with ANAVEX®2-73 A higher Cohen’s d implies less paBents are needed to show a significant difference between placebo arm and ANAVEX®2-73 arm in a clinical study Improvement of Scores in Week 57 from Baseline Excl. of SIGMAR1 Pro2

  27. Slide 27: ANAVEX2-73 Phase 2b/3 Alzheimer's Disease Ongoing Study

    Slide 27: ANAVEX2-73 Phase 2b/3 Alzheimer's Disease Ongoing Study

    ANAVEX®2-73 Phase 2b/3 Alzheimer's Disease Ongoing Study Primary Endpoints at 48 N=450 ANAVEX®2-73 Weeks High dose# • ADAS-Cog Early AD paBent • ADCS-ADL populaBon • RandomizaBon 1:1:1 Safety and tolerability of • Confirmed amyloid ANAVEX®2-73 pathophysiology (CSF/ amyloid PET) Key Secondary Endpoint

  28. Slide 28: Creating a Precision Medicine Franchise: Omic Platform

    Slide 28: Creating a Precision Medicine Franchise: Omic Platform

    CreaBng a Precision Medicine Franchise ANAVEX®2-73 MulBple Omic Plaporm Longitudinal longitudinal end Extensive Novel target trial, extensive Points MulBple Genomics SIGMAR1 PK/PD, (cogniBon: potenBal (homeostasis) IniBal safety MMSE, from NGS indicaBons established funcBon: ADCS- (RNA, DNA) ADL) 28

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks